Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Euphrasia eye drops are a botanical preparation derived from the *Euphrasia officinalis* plant, commonly known as Eyebright. Manufactured by Weleda, these drops are used in complementary medicine for their purported anti-inflammatory and astringent properties to treat eye irritation, redness, and discharge. The University of Bern investigated the formulation in a randomized, double-blind, placebo-controlled trial (NCT04122300) specifically for preterm neonates suffering from congenital nasolacrimal duct obstruction (CNLDO). The study aimed to determine if early administration could resolve ocular discharge and reduce the necessity for topical antibiotics. While the primary outcome of treatment success did not reach statistical significance compared to placebo, the results suggested potential symptomatic benefits for secondary signs such as eye reddening and tearing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Euphrasia eye drops.